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Table 1. Post-AHSCT Patient Toxicities
Patients with
ONJ (N510)
Control Group
(N540) p-value
Febrile days
Mean (Std dev) 2.20 (3.12) 3.30 (3.83) 0.524
Range 0-9 0-15
Lenght of hospital stay in days
Mean (Std dev) 18.20 (7.76) 18.58 (8.44) 0.541
Range 13-38 11-59
Days to ANC engraftment
Mean (Std dev) 10.30 (0.95) 10.58 (1.13) 0.482
Range 9-12 9-15
Days to platelet engraftment
Mean (Std dev) 12.20 (1.62) 12.48 (2.91) 0.776
Range 10-15 10-24
Nausea/Vomiting
Grade 0 (%) 1 (10) 2 (5) 0.753
Grade 1 (%) 3 (30) 21 (52.5)
Grade 2 (%) 6 (60) 15 (37.5)
Grade 3 (%) 0 (0) 2 (5)
Mucositis
Grade 0 (%) 4 (40) 13 (35.5) 0.889
Grade 1 (%) 2 (20) 12 (30)
Grade 2 (%) 3 (30) 11 (27.5)
Grade 3 (%) 1 (10) 4 (10)
Diarrhea
Grade 0 (%) 0 (0) 4 (10) 0.261
Grade 1 (%) 1 (10) 9 (22.5)
Grade 2 (%) 4 (40) 11 (27.5)
Grade 3 (%) 5 (50) 15 (37.5)
Poster Session I S275allogeneicHCT’s. ADV infection was documented in 19 (25%). The
initial site of infection wasGI in 18 andGU in 1. Initial findings were
stool pcr or culture of stool or GI biopsy simultaneous with viremia
in 1. Plasma pcr’s were performed in 11 cases and viremia was found
0-11 days after GI detection in 10. This delay may reflect the way
monitoring was performed rather than any characteristic of ADV in-
fection. All patients except 2 received treatment with CDV 1mg/kg
3x per week. There were 4 cases in 34 patients receiving grafts
from family donors (12%). The incidence in patients receiving
HCT from unrelated donors was 3 fold greater 15/42 (36%). In
both groups 3/4 of ADV infections were preceded by clinically signif-
icant GVHD (3 of 4 sibling HCT and 11 of 15 unrelated HCT).
Since GVHD occurs more commonly after unrelated HCT we
looked at incidence of ADV infection using GVHD and transplant
type as risk factors. 22 of 42 (52%) recipients of unrelated HCT de-
veloped GVHD and 11 ADV infections (50%) occurred in these pa-
tients. Among recipients of relatedHCT 11 of 34 developedGVHD
and 3 of these ADV infection (27%) compared to1 of 23 (4%) devel-
oping ADV without prior GVHD. Most cases developing ADV in-
fection after GVHD had a typical time course, occurring 30-80
days after HCT and 1-8 weeks of steroid therapy. In contrast, 5 cases
occurring without GVHD occurred in patients with congenital im-
mune deficiency or after 2cd and 3rdHCT’s for relapse. Survival was
80% (4 of 5) in patients with ADV infection occurring before or in
absence of GVHD (median 2yr). For patients with GVHD and
ADV infection treatment success was 3 of 11 for unrelated HCT
and 3 of 4 for related HCT. Most deaths were due to combination
of toxicity and GVHD usually after control of ADV infection with
C. ADV infection after HCT correlates closely with GVHD and
unrelated donor graft. Treatment success depends both treatment
of associated GVHD and organ toxicity as it does supression of
ADV.Grade 4 (%) 0 (0) 1 (2.5)
Bacteremia
Yes (%) 3 (30) 12 (30) 1.000
Mean (Std dev) were examined by Student T-test. Frequency (%) were
examined by Mantel-Haenszel Chi-Square.334
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Background: The incidence of bisphosphonate-induced osteonec-
rosis of the jaw (BONJ) in patients with multiple myeloma (MM)
is estimated to be between 5-15%. It is unknown if BONJ canworsen
mucositis or impair its healing. Another concern is that necrotic
bone can harbor bacteria or other microorganisms that can cause
bacteremia and infection during prolonged periods ofmyelosuppres-
sion resulting in more severe toxicity after autologous stem cell
transplantation (AHSCT). The purpose of this study was to deter-
mine if transplant-associated toxicities in patients with BONJ was
different from patients without BONJ.
Patients andMethods:Using a retrospective case-control study de-
sign, 10 MM patients that met diagnostic criteria for BONJ prior to
AHSCT at our institution, between June 2005 and June 2010, were
matched to 40 MM patients without BONJ from our program’s da-
tabase. Patients were matched based on age, stage, gender, ethnicity,
performance status and conditioning regimen prior to AHSCT.
Pre-transplant factors analyzed included: smoking, type of bi-
sphosphonate received and number of infusions, dental extractions
1-year pretransplantation and total edentia. Posttransplant toxicities
analyzed included: mucositis, nausea/vomiting, diarrhea, bacter-
emia, febrile days, engraftment, and length of hospital stay.
Results: The incidence and severity of all toxicities analyzed were
similar in both groups including mucositis, bacteremia and febrile
days (see table). Engraftment and hospital stay were also similar.
Of interest, patients with history of smoking were associated with
a higher risk of BONJ (OR, 4.5; 95% CI, 1.05-19.25, p 5 0.043).
Despite the fact that patients who underwent dental extractions
within one year of AHSCT did not experience a higher risk of
BONJ, total edentia was associated with a significant increase of
BONJ risk (OR, 8.5; 95% CI, 1.83-9.42, p 5 0.006). Type of bi-
sphosphonate and number of infusions received did not increase
the risk of BONJ in our study.Conclusions: Oral and systemic posttransplant complications of
patients with BONJ were similar to patients without BONJ in this
case-control study. The outcome of this study suggests that AHSCT
can be performed safely in patients with BONJ. In our analysis,
patients who smoked and edentulous patients were at higher risk
of developing BONJ.335
EMPRIRICAL ANTIFUNGAL THERAPY OF PERSISTENT NEUTROPENIC FE-
VER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION WITH CASPOFUNGIN OR LIPOSOMAL AMPHOTERICIN B
Sanz, J., Pellicer, D., Montesinos, P., Martinez, D., Salavert, M.,
Lorenzo, I., Palau, J., Martın, G., Jarque, I., de la Rubia, J.,
Moscardo, F., Martinez, J., Sanz, G., Sanz, M.A. Hospital Universitario
La Fe, Valencia, Spain
Caspofungin and liposomal amphotericin B (L-ampho B) have
shown similar efficacy for the treatment of persistent febrile neutro-
penia (PFN). Although patients undergoing allogeneic stem cell
transplantation (allo-SCT) are at high risk of life-threatening inva-
sive fungal infections (IFI), specific data on the best choice of anti-
fungal agent in this setting are scarce.
The aim of the present study was to analyse the efficacy of caspo-
fungin and L-ampho B used as empirical treatment of PFN in two
consecutive historical cohorts of patients undergoing allo-SCT at
a single institution. Efficacy was evaluated using a five-part compos-
ite end point.
From 2000 to 2009, we analyzed 134 consecutive patients under-
going allo-SCT who received empirical antifungal therapy for the
treatment of PFN: a first cohort of 61 patients treated with L-ampho
B (2000-2004) vs a second cohort of 73 patients treated with caspo-
fungin (2005-2009). Most baseline characteristics were comparable
between both groups. However, patients in the caspofungin group
received more unrelated donor cord blood transplants (63% vs
41%, p 5 0.011).
S276 Poster Session IBreakthrough fungal infections were observed in 4 (6%) and 11
(15%) patients in the L-ampho B and the caspofungin groups, re-
spectively (p 5 0.2). Of all, 13 were due to Aspergillus spp while 1
C. neoformans CNS infection and 1 B. capitatus fungemia were ob-
served in patients receiving caspofungin. Nine additional patients
had a baseline fungal infection (4 in the L-ampho B group and 5 in
the caspofungin group) and none of them had successful treatment.
Resolution of fever during neutropenia was seen in 40 (66%) and 41
(56%) of patients in the L-ampho B and the caspofungin groups,
respectively (p5 0.17). There was a trend towards higher premature
discontinuation of therapy due to lack of efficacy or toxicity in the
caspofungin group (27% vs 13%, p 5 0.057). However, more pa-
tients survived at least 7 days after completion of therapy in the cas-
pofungin group (92% vs 75%, p 5 0.007). The overall success rate
defined as the fulfilment of all 5 composite end points was achieved
in 28 (46%) and 24 (33%) patients in the L-ampho B and the caspo-
fungin groups, respectively (p 5 0.16).
L-ampho B and caspofungin were both effective when given as
empirical antifungal therapy for the treatment of PFN in patients un-
dergoing allogeneic SCT. Differences between L-ampho B and cas-
pofungin in overall success assessed by the 5-component end point
were not statistically significant.336
RE-IMMUNIZATION PRACTICES AMONG SURVIVORS OF PEDIATRIC
HEMATOPOIETIC STEM CELL TRANSPLANT
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Background:The number of Hematopoietic StemCell Transplants
(HSCT) has increased over the past 25 years with higher rates of
success and a large number of long-term survivors. Patients who un-
dergo either an autologous or allogeneic HSCT experience pro-
found immunosuppression from the conditioning regimen causing
them to lose the immunity gained from previous vaccinations. Ac-
knowledging the need for consistency among practices, the Centers
for Disease Control and Prevention, Infectious Disease Society of
America, and the American Society of Blood and Marrow Trans-
plantation published guidelines regarding re-immunization post
HSCT in 2000.
Purpose: The purpose of this study was to assess patient adherence
to re-immunization guidelines after HSCT. Completeness, timeli-
ness, factors influencing adherence and parental identification of
barriers to re-immunization were also examined.
Methods: Patients who received anHSCTbetween 01/01/2001 and
12/31/2007 and were alive at time of recruitment were eligible for
enrollment. Parents of eligible patients were contacted to participate
in a phone survey assessing perceptions of and barriers to re-immu-
nization. Vaccination data was abstracted using theGeorgia Registry
of Immunization Transactions and Services (GRITS), a state-wide
mandatory reporting database for Georgia.
Results: Of the 271 patients transplanted during the designated
time period, 98 met eligibility criteria and 58 completed the phone
survey. Of the phone survey participants, 90% (N 5 58) reported
being told their child would need to be re-immunized post HSCT
and 89% (N 5 57) reported their child being up to date on immu-
nizations to the best of their knowledge. Data in GRITS, however,
showed that only 9% (N 5 98) had completed all doses of 6 of the
recommended vaccines (Hep B, HiB, MMR, Polio, PPV, DTaP/
Td). On average patients who had received at least one post-
HSCT vaccination completed 60% of the recommended doses
(N 5 87). Patients who received allogeneic transplants averaged
63% (N 5 56) complete while patients who received autologous
averaged 54% (N 5 31) complete. The guidelines recommend pa-
tients begin re-immunization 365 days post HSCT. The average
time to first immunization post HSCT was 639 days (median
512 days, range 195 – 2728 days).
Conclusion: Parents perceived their children to be more up to date
with their re-immunizations than was found in GRITS data. Further
education is needed for both parents and healthcare providers caring
for these patients.337
BIOAVAILABILITY OF ORALLY ADMINISTERED VORICONAZOLE AND ITS
ASSOCIATION WITH THE EFFECTS ON TACROLIMUS CONCENTRATION
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Mori, T., Kato, J., Yamane, A., Okamoto, S. Keio University School of
Medicine, Tokyo, Japan
Backgrounds: Although drug interaction between calcineurin in-
hibitors and voriconazole has been recognized, the interaction has
not been fully evaluated in hematopoietic stem cell transplantation
(HSCT) recipients. We have previously shown a notably wide vari-
ability in the effect of voriconazole administration on the concentra-
tion of calcineurin inhibitors in HSCT recipients, in whom
voriconazole and calcineurin inhibitors were administered orally or
intravenously (Bone Marrow Transplant 2009;44:371). In the pres-
ent study, the drug interaction between voriconazole and tacrolimus
was evaluated in HSCT recipients, when both were orally adminis-
tered. In addition, bioavailability of voriconazole was evaluated
and its association with the drug interaction was quantitatively
assessed.
Patients & Methods: Twenty-two recipients of allogeneic HSCT
who had already been on a steady dose of orally administered tacro-
limus, and were started on voriconazole (orally 200 mg per body ev-
ery 12 h) for the treatment or prophylaxis of fungal infection were
evaluated. Conditioning were myeloablative in 12 patients, and re-
duced-intensity in 8 patients. The concentration/dose (C/D; (ng/
ml)/(mg/kg)) ratio of calcineurin inhibitors was calculated before
and 7–10 days after initiating voriconazole administration. The C/
D ratios before and after voriconazole administration were com-
pared, and increased rate (%) was calculated. The plasma level of
voriconazole was measured by high-performance liquid chromatog-
raphy.
Results:Themedian C/D ratio of tacrolimus significantly increased
to 531.1 (ng/ml)/(mg/kg) (range, 127.8-759.2) after initiating vori-
conazole administration as compared with that before (169.6 (range,
128.6-541.3): P\0.001). Median increased rate of C/D ratios were
196.8% with a range of -32.0% to 685.7%. The plasma level of vor-
iconazole on the day of evaluating C/D ratio was 2.3961.67 mg/ml,
which was lower than 1.0 mg/ml in 4 patients and higher than 4.0
mg/ml in 3 patients. The increased rate of C/D ratio of tacrolimus
did not correlate with the plasma level of voriconazole (r 5 -0.05,
P 5 0.838).
Conclusion: Orally administered voriconazole demonstrates
a significant interaction with orally administered tacrolimus with
a wide interindividual variability in the magnitude. A wide interindi-
vidual variability could not be explained by the difference in the bio-
availability of voriconazole, and other mechanisms such as p-gp
should be investigated.338
TREATMENT OF PARAINFLUENZA 3 INFECTION WITH DAS181 IN A PA-
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Parainfluenza virus (PIV) infections are common after allogeneic
SCT and can cause severe morbidity, yet there is no effective treat-
ment. DAS181 is an investigational antiviral medication which is ac-
tive in vitro and in vivo against PIV. It is a recombinant sialidase
protein which removes sialic acid residues. Binding to these residues
is the initial step in PIV infection. We report the first treatment of
PIV3 infection with DAS181 in a SCT patient. A 63 year-old female
with AMLunderwent a second SCT after primary graft failure. Con-
ditioning included fludarabine and alemtuzumab, with tacrolimus as
GVHD prophylaxis. After engraftment, her course was complicated
by grade III skin GVHD which was treated with steroids and myco-
phenolate mofetil. Three months after her second SCT, she devel-
oped nasal congestion and cough and was found to have PIV3
infection. She was treated with bronchodilators and IVIG. There
was no evidence of superinfection. She was admitted 6 weeks later
for pancytopenia and worsening respiratory status thought to be
from progressive PIV3 infection. Given her worsening status, we ob-
tained an emergency IND from the FDA to administer DAS181.
